An investigation of the inhibitory effects of dendrosomal nanocurcumin on Candida albicans and systemic candidiasis in BALB/c mice

Katirae F1*, Ashrafai Helan J1, Emami SJ1, Hamidian Gh2, Babaei E3

1 Department of Pathobiology, Faculty of Veterinary Medicine, University of Tabriz, Tabriz, Iran
2 Department of Basic Sciences, Faculty of Veterinary Medicine, University of Tabriz, Tabriz, Iran
3 Department of Genetics, Faculty of Basic Sciences, University of Tabriz, Tabriz, Iran

*Corresponding author: Farzad Katirae F, Division of Clinical Mycology, Department of Pathobiology, Faculty of Veterinary Medicine, University of Tabriz, Tabriz, Iran. Email: katirae_f@yahoo.com

(Received: 16 November 2015; Revised: 9 January 2016; Accepted: 10 February 2016)

Abstract

Background and Purpose: Use of curcumin, as a promising antifungal agent, is considered an alternative treatment for fungal infections; however, the low solubility of this agent limits its efficacy. Accordingly, in this study, we aimed to evaluate the in vitro and in vivo antifungal activities of dendrosomal nanocurcumin with improved solubility and bioavailability.

Materials and Methods: The in vitro antifungal activities of several Candida species, including C. albicans, C. tropicalis, C. krusei, C. dubliniensis, and C. dubliniensis, were evaluated, using the broth microdilution method. In the in vivo study, different doses of nanocurcumin (5, 10, 20, and 40 mg/kg) were administered to mice with systemic C. albicans infection via intraperitoneal injection. All mice were euthanized at 20 days following the administration of different doses of nanocurcumin. Different organs were extracted for organ culture and histopathological examination.

Results: Based on the findings, 40 mg/kg of nanocurcumin significantly decreased the fungal load in the evaluated organs; the results were confirmed with histopathological examination. The kidney was found to be the most affected organ with the highest number of severe lesions. Yeasts and pseudohyphae were observed in the blood vessels, kidney, and brain. Also, yeasts were present in the liver, brain, lungs, and heart of the control group.

Conclusion: Although curcumin is generally an excellent antifungal component, its nano-sized form showed more potent properties. Based on the gathered data, dendrosomal nanocurcumin is an effective antifungal agent with good efficacy against disseminated candidiasis. However, further studies are required to evaluate the effects of dendrosomal nanocurcumin on other fungal infections. Also, this agent could be useful for the prevention of fungal infections, such as candidiasis, particularly in high-risk patients.

Keywords: Candida albicans, Systemic candidiasis, Antifungal, Nanocurcumin

How to cite this paper:
Katirae F, Ashrafai Helan J, Emami SJ, Hamidian Gh, Babaei E. An investigation of the inhibitory effects of dendrosomal nanocurcumin on Candida albicans and systemic candidiasis in BALB/c mice. Curr Med Mycol. 2016; 2(1): 7-12. DOI: 10.18869/acadpub.cmm.2.1.7

Introduction

The occurrence of fungal infections has significantly increased since 1980’s as a consequence of the indiscriminate use of broad-spectrum antibiotics and the growing number of immunocompromised individuals [1, 2]. Candida species are major yeasts isolated from clinical infections. The genus Candida is composed of several species, which are found in the normal flora of the mucosal oral cavity, gastrointestinal tract, and vagina [2].

Candida species are commensal in humans and animals and remain responsible for several clinical manifestations, such as mucosal and skin overgrowth or bloodstream infection, especially in immunocompromised patients or cases with the elimination of normal flora [3]. Although C. albicans is the major cause of invasive infection, other species such as C. parapsilosis, C. tropicalis, and C. glabrata are also involved [4].

The National Nosocomial Infections Surveillance (NNIS) system report in the United States has introduced Candida species as the major cause of infection in immunocompromised patients [5]. The need for the development or improvement of antifungal agents is growing, considering the limited number of these agents,
compared to antibacterial drugs. Azoles are routinely used to combat *Candida* species. However, owing to their dominant fungistatic activities, fungal resistance may occur, especially due to long-term use. In fact, azole-resistant *Candida* strains still remain a major challenge for clinicians [6]. Furthermore, some antifungal agents exert adverse side-effects such as nephrotoxicity [7].

Recently, several strategies, such as combination therapy and use of herbal medicines, such as allicin, berberine, grapefruit seed extracts, tea tree oil, and curcumin, have been used for the treatment of fungal infections. Among the introduced strategies, curcumin, a phenolic component derived from the rhizomes of *Curcuma longa*, has been widely used, given its anti-cancer, anti-inflammatory, antioxidant, and anti-infection properties.

The *in vitro* antifungal activity of curcumin against several fungal strains, such as *Candida* and *Aspergillus* species, has been confirmed in recent studies [6, 8]. According to the literature, curcumin shows better antifungal activities against *Paracoccidioides brasiliensis* and *Sporothrix schenckii*, compared to fluconazole [9]. Curcumin is believed to exert its antifungal effects through altering the membrane-associated properties of ATPase activity, ergosterol biosynthesis, proteinase secretion, and apoptosis induction [10].

In spite of its promising pharmaceutical characteristics, curcumin exhibits poor aqueous solubility and fast biodegradation [11]. Several approaches, such as treatment with adjuvants, liposomes, and more recently nanoparticles, have been applied to overcome this limitation. According to the literature, dendrosomal nanoparticles markedly enhance the therapeutic efficacy of curcumin by improving its solubility [12]. Therefore, in the present study, we aimed to describe the *in vitro* antifungal activity of dendrosomal nanocurcumin against *Candida* species and systemic candidiasis in mice.

**Materials and Methods**

**Reagents and strains**

The reference strains of *C. albicans* (ATCC 10231), *C. tropicalis* (ATCC 750), *C. krusei* (PTCC 5295), *C. parapsilosis* (ATCC 22019), and *C. dubliniensis* (CD36) were used in the present study. To prepare the inoculum, the procedures for producing dendrosomal curcumin were performed as described in the literature [12] at the Faculty of Natural Sciences, University of Tabriz, Tabriz, Iran.

**In vitro antifungal activity**

The strains were cultured on Sabouraud dextrose agar (SDA) at 30°C for 48 h before the experiments. The proper concentration of the prepared *Candida* suspension was adjusted by the hemocytometer. As described by the Clinical & Laboratory Standards Institute (CLSI) document M27-S4 [13], broth microdilution method was used to determine the *in vitro* minimum inhibitory concentration (MIC) of nanocurcumin against the strains. MIC was determined as the lowest concentration resulting in fungal growth inhibition.

The broth microdilution method was performed in flat-bottomed 96-well microtiter plates, using RPMI-1640 medium, which had been buffered to a pH of 7.0 with 0.165 M of morpholinepropanesulfonic acid (Sigma, USA). Then, 100 µl of nanocurcumin (4%) was added to the first well, containing 100 µl of the medium, followed by twofold serial dilution. An inoculum size of 0.5–2.5×10³ CFU/ml was prepared spectrophotometrically and added to each well. The plates were incubated at 35°C for 48 h. The tests were performed in triplicate on separate plates.

**Animals**

In total, 25 healthy female BALB/c mice (4–6 weeks old), weighing 18–22 g, were used in this study. The mice were purchased from Pasteur Institute of Iran (Tehran, Iran) and kept in the experimental animal laboratory of Tabriz University. The animals were housed in stainless steel cages and fed standard pellets and water ad libitum (80% humidity, temperature of 37°C) in a 12:12 h light/dark cycle.

**Treatment**

After one week of acclimatization, the mice were randomly divided into five groups (five mice per group) to receive different treatments. The mice were infected by intravenous injection of 0.5×10⁷ of saline-washed *C. albicans* blastospore reference strain. In group I, the first dose of nanocurcumin (5 mg/kg) was administered via intraperitoneal injection two days after the injection.
before the inoculation of *C. albicans*; the next dose was injected two days after inducing infection in mice.

Treatment groups II, III, and IV received nanocurcumin at doses of 10, 20, and 40 mg/kg, respectively via intraperitoneal injection at 24 h following the injection. Nanocurcumin injection was repeated every 24 h over one week for these treatment groups (II, III, and IV). On the other hand, the control group received no treatments after the intravenous injection of *C. albicans*. All mice were euthanized at 20 days following the administration of different doses of nanocurcumin.

**Organ culture**

At the end of the exposure, the animals were sacrificed by ether anesthesia. Whole specimens were obtained from the brain, lungs, liver, intestine, kidney, and spleen of mice. A section of aseptically-collected organs was homogenized by a porcelain mortar and pestle, and 0.1 g of the homogenized tissue was placed on SGA in a plate. The plates were incubated at 35°C for 48 h, and the number of colony-forming units (CFUs) per 0.1 g of each tissue was determined. The organ cultures were conducted in duplicate.

**Histopathology**

At the end of the exposure, the collected organs were examined for gross pathological lesions. The portions of different organs were fixed in 10% neutral buffered formalin. After routine histological procedures, paraffin blocks were divided into 5 µm thick sections, stained with hematoxylin and eosin (H&E) and periodic acid–Schiff (PAS) methods. Afterwards, they were examined under a light microscope for the assessment of *C. albicans* foci, blastoconidia, and pseudohyphae in the organs and evaluation of the intensity of the inflammatory response.

### Results

#### MIC results

The MICs for curcumin and nanocurcumin are presented in Table 1. The antifungal effects of nanocurcumin were at least twice as high as curcumin.

| *Candida* species | MIC (mg/ml) Nanocurcumin | Curcumin |
|------------------|--------------------------|----------|
| *C. albicans*    | 0.5                      | 2        |
| *C. tropicalis*  | 0.5                      | 1        |
| *C. krusei*      | 1                        | 2        |
| *C. parapsilosis*| 0.5                      | 1        |
| *C. dubliniensis*| 0.5                      | 1        |

The observed lesions included myocardial necrosis and hemorrhage in the heart; however, no fungal organism was found in the heart.

The liver showed fatty changes and necrotic areas surrounded with lymphocytes and macrophages; also, blastoconidia of *C. albicans* were present in the samples. In the corpus callosum, axonal swelling, leukoencephalopathy, **Table 1. Minimum inhibitory concentrations (MICs) of curcumin and nanocurcumin against *Candida* species**
and gliosis were observed. Furthermore, in all treatment groups, histopathological lesions with varying severities were observed, based on the received treatment.

**Discussion**

Evaluation of antifungal agents used for the treatment of disseminated candidiasis has revealed treatment failure, occurrence of side-effects, and high rate of disease relapse. Consequently, major efforts have been made to identify natural agents in order to overcome these opportunistic infections. Several studies have investigated the antimicrobial activity of curcumin and its analogues against pathogenic fungi, bacteria, viruses, and protozoa.

In the present study, we characterized the *in vitro* antifungal activity and effects of different doses of dendrosomal nanocurcumin on histopathological results and fungal burden in an experimental model of systemic candidiasis among BALB/c mice. Curcumin, given its useful properties such as adequate safety and extended antimicrobial activity, has attracted researchers’ attention. In the present study, dendrosomal nanocurcumin, as a more soluble form of curcumin, was used in order to increase its efficacy.

In this regard, Babaei *et al.* (2012) by using *in vitro* and *in vivo* models reported enhanced bioavailability and anti-cancer efficacy of dendrosomal curcumin, compared with void curcumin due to enhanced solubility and improved curcumin uptake mediated by dendrosomes [14]. Overall, dendrosomes are found to be safe components with no adverse side-effects on natural cells. In this study, we observed that 0.5-1 mg/ml of dendrosomal curcumin could significantly affect the growth of *C. albicans* and non-*C. albicans* species.

Furthermore, Bhawana *et al.* (2011) prepared nano-sized curcumin, using the wet-milling technique. The results showed improved water solubility (without any surfactants), attributed to the narrow size and larger surface area of particles, resulting in enhanced dissolution and bioa-vailability [15]. The *in vitro* antimicrobial assay using agar dilution and well-diffusion methods revealed that nanocurcumin has more significant antimicrobial activities, compared to curcumin against the selected bacteria and fungal strains (e.g., *Penicillium notatum* and *Aspergillus niger*). This finding could be attributed to the smaller particle size and higher water solubility of nanocurcumin (without any modifications in its structure) [16].

Based on the present findings, the antifungal activity of dendrosomal nanocurcumin was at least twice as good as curcumin against *C. albicans* and non-*C. albicans* species. In line with the current research, better solubility and bioavailability of nanocurcumin and its marginal advantage over curcumin in combating some bacterial strains have been reported in different studies [16, 17].

According to the literature, curcumin is well tolerated by the body even at high doses [16, 17]. However, this agent has low bioavailability and its uptake is limited to epithelial cells of the intestine [18], resulting in a decline in systemic exposure and pharmacological activity. Although in the present study, pretreatment (5 mg/kg) and some post-treatment (10, 20 mg/ml) doses did not result in a significant decline in fungal burden in systemic candidiasis, 40 mg/kg of dendrosomal curcumin significantly decreased the fungal load, compared to the control group.

Dendrosomal nanocurcumin is probably absorbed more easily into the bloodstream than curcumin. In line with the present study, Sharma *et al.* (2010) reported that 100 mg/kg of curcumin was unable to decrease the fungal load. However, its combination with piperine (an inhibitor of hepatic and intestinal glucuronidation) significantly eradicated the fungal load in the kidney [10].

In the present study, most colonies were recovered from the kidney, although other organs were affected, as well. In a previous study on systemic candidiasis in a dog model, lungs were found to be the most affected organs with the

| Nanocurcumin dose     | Mean CFU/0.1 g |
|-----------------------|---------------|
|                       | Kidney | Liver | Spleen | Lung | Brain |
| Nanocurcumin (5 mg/kg) | 16.8   | 9.2   | 2.2    | 7.2  | 9.4   |
| Nanocurcumin (10 mg/kg) | 17     | 8.2   | 1.4    | 6    | 7.8   |
| Nanocurcumin (20 mg/kg) | 11.6   | 3.6   | 0      | 1.2  | 2.4   |
| Nanocurcumin (40 mg/kg) | 0.6    | 0     | 0      | 0.2  | 0.2   |
| Untreated (control)   | 17.4   | 10.2  | 2.2    | 9.2  | 12.6  |
highest fungal burden. The observed discrepancy might be attributed to the use of different animal models, pharmacodynamic and pharmacokinetic factors, and timing and dosage of antifungal regimens. Histopathological findings also confirmed the accuracy of organ culture results, as no fungal structure was found in the group receiving 40 mg/kg of nanocurcumin.

In conclusion, the gathered data suggested that dendrosomal nanocurcumin is an effective antifungal agent with good efficacy against disseminated candidiasis. However, further studies are required to evaluate the effect of dendrosomal nanocurcumin on other fungal infections. Also, this agent could be helpful for the prevention of fungal infections, such as candidiasis, particularly in high-risk patients.

Acknowledgements
This study was extracted from a Doctor of Veterinary Medicine (DVM) thesis and was funded by the University of Tabriz, Tabriz, Iran.

Authors’ contributions
F.K. and E.B. designed the research, F.K and J.A. supervised the study, and F.K. and J.A. edited the final manuscript. SJ.E. and G.H. performed the in vitro tests, while F.K. and E.B. performed the in vivo tests.

Conflicts of interest
The authors declare no conflicts of interest.

Financial disclosure
There was no financial interest related to the materials of the manuscript.

References
1. Enoch DA, Ludlam HA, Brown NM. Invasive fungal infections: a review of epidemiology and management options. J Med Microbiol. 2006; 55(Pt 7):809-18.
2. Sardi JC, Scorzon L, Bernardi T, Fusco-Almeida AM, Mendes Giannini MJ. Candida species: current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options. J Med Microbiol. 2013; 62(Pt 1):10-24.
3. Eggimann P, Garbino J, Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis. 2003; 3(11):685-702.
4. Liguori G, Di Onofrio V, Galle F, Lucariello A, Albano L, Catania MR, et al. Candida albicans identification: comparison among nine phenotypic systems and a multiplex PCR. J Prev Med Hyg. 2010; 51(3):121-4.
5. Dovigo LN, Pavarina AC, Carmello JC, Machado AL, Brunetti IL, Bagno VS. Susceptibility of clinical isolates of Candida to photodynamic effects of curcumin. Lasers Surg Med. 2011; 43(9):927-34.
6. Sharma C, Kumar N, Meis JF, Pandey R, Chowdhary A. Draft Genome sequence of a fluconazole-resistant candida auris strain from a candidemia patient in India. Genome Announcs. 2015; 3(4):1-2.
7. Laniado-Laborin R, Cabrales-Vargas MN. Ampthotericin B: side effects and toxicity. Rev Iberoam Micol. 2009; 26(4):223-7.
8. Martins CV, da Silva DL, Neres AT, Magalhaes TF, Watanabe GA, Modolo LV, et al. Curcumin as a promising antifungal of clinical interest. J Antimicrob Chemother. 2009; 63(2):337-9.
9. Neelofar K, Shreaz S, Rimple B, Muralidhar S, Nikhat M, Khan LA. Curcumin as a promising antifungal of clinical interest. Can J Microbiol. 2011; 57(3):204-10.
10. Sharma M, Manoharal R, Puri N, Prasad R. Antifungal curcumin induces reactive oxygen species and triggers an early apoptosis but prevents hyphae development by targeting the global repressor TUP1 in Candida albicans. Biosci Rep. 2010; 30(6):391-404.
11. Flora G, Gupta D, Tiwari A. Nanocurcumin: a promising therapeutic advancement over native curcumin. Crit Rev Ther Drug Carrier Syst. 2013; 30(4):331-68.
12. Aas Z, Babaei E, Hosseinpour Feizi MA, Dehghan G. Anti-proliferative and apoptotic effects of dendrosomal farnesiferol C on gastric cancer cells. Asian Pac J Cancer Prev. 2015; 16(13):5325-9.
13. Fothergill AW, Sutton DA, McCarthy DJ, Wiederhold NP. Impact of new antifungal breakpoints on antifungal resistance in Candida species. J Clin Microbiol. 2014; 52(3):994-7.
14. Babaei E, Sadeghizadeh M, Hassan ZM, Feizi MA, Najafi F, Hashemi SM. Dendrosomal curcumin significantly suppresses cancer cell proliferation in vitro and in vivo. Int Immunopharmacol. 2012; 12(1):226-34.
15. Bhawana P, Basniwal RK, Buttar HS, Jain VK, Jain N. Curcumin nanoparticles: preparation, characterization, and antimicrobial study. J Agric Food Chem. 2011; 59(5):2056-61.
16. Pai MP, Turpin RS, Garey KW. Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia. Antimicrob Agents Chemother. 2007; 51(1):35-9.
17. Javidi MA, Zolghadr F, Babashah S, Sadeghizadeh M. Introducing dendrosomal nanocurcumin as a compound capable of in vitro eliminating undifferentiated stem cells in cell therapy practices. Exp Clin Endocrinol Diabetes. 2015; 123(10):632-6.
18. Sharma RA, McLelland HR, Hill KA, Ireson CR, Euden SA, Manson MM, et al. Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res. 2001; 7(7):1894-900.